Log in
Enquire now
‌

US Patent 7884197 Synthetic agonists of TLR9

Patent 7884197 was granted and assigned to Idera Pharmaceuticals on February, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Idera Pharmaceuticals
Idera Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
78841970
Patent Inventor Names
Mallikarjuna Putta0
Sudhir Agrawal0
Daqing Wang0
Dong Yu0
Ekambar Kandimalla0
Lakshmi Bhagat0
Date of Patent
February 8, 2011
0
Patent Application Number
119547260
Date Filed
December 12, 2007
0
Patent Citations Received
‌
US Patent 11957788 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
0
Patent Primary Examiner
‌
Dana Shin
0
Patent abstract

The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7884197 Synthetic agonists of TLR9

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.